A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Philip Kantoff, MD
Dana-Farber Cancer Institute
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
220 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Sydney Haematology and Oncology Clinic
St Leonards, New South Wales, Australia
- Calvary Mater Newcastle
Waratah, New South Wales, Australia
- Redcliffe Hospital
Redcliffe, Queensland, Australia
- Royal Adelaide Hospital
Adelaide, South Australia, Australia
- Austin Hospital
Heidelberg, Victoria, Australia
- Monash Medical Centre - Moorabbin Campus
Bentleigh East, Australia
- Barwon Health
Geelong, Australia
- St John of God Hospital
Subiaco, Australia
- Border Medical Oncology
Wodonga, Australia
- Princess Alexandra Hospital
Woolloongabba, Australia
- Ziekenhuisnetwerk Antwerpen - Az Middelheim
Antwerp, Belgium
- Cliniques Universitaires Saint-Luc
Brussels, Belgium
- Institut Jules Bordet
Brussels, Belgium
- Az Maria Middelares
Ghent, Belgium
- Uz Leuven
Leuven, Belgium
- H.-Hartziekenhuis Roeselare-Menen Vzw
Roeselare, Belgium
- Southern Interior Medical Research Inc.
Kelowna, British Columbia, Canada
- Capital District Health Authority
Halifax, Nova Scotia, Canada
- Brantford Urology Research
Brantford, Ontario, Canada
- Cambridge Memorial Hospital
Cambridge, Ontario, Canada
- St. Josephs Healthcare Hamilton Research Ethics Board
Hamilton, Ontario, Canada
- Queen'S University at Kingston
Kingston, Ontario, Canada
- London Health Sciences Centre
London, Ontario, Canada
- the Female/male Health Centres
Oakville, Ontario, Canada
- Princess Margaret Hospital
Toronto, Ontario, Canada
- Centre Hospitalier de L'Universite de Montreal
Montreal, Quebec, Canada
- Centre Hospitalier Universitaire de Quebec Hotel Dieu
Québec, Canada
- Aalborg Sygehus
Aalborg, Denmark
- Rigshospitalet
Copenhagen, Denmark
- Frederiksberg Hospital
Frederiksberg, Denmark
- Herlev Hospital
Herlev, Denmark
- Holstebro Sygehus
Holstebro, Denmark
- Storstrømmens Sygehus Næstved
Næstved, Denmark
- Skejby Sygehus
Århus N, Denmark
- East Tallinn Central Hospital
Tallinn, Estonia
- North Estonia Medical Centre Foundation
Tallinn, Estonia
- Tartu University Hospital
Tartu, Estonia
- Centre Paul Papin
Angers, France
- Centre Hospitalier Départemental la Roche Sur Yon, Luçon, Montaigu - Les Oudaries
La Roche-sur-Yon, France
- Centre Léon Bérard - Centre Régional de Lutte Contre Le Cancer Rhône-Alpes
Lyon, France
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 28 Nov 2011
- Primary completion
- 25 Sept 2017
- Completion
- 15 Dec 2017
- Last update posted
- 4 Sept 2019
- Registered enrollment
- 1,297
- Registry id
- NCT01322490
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.